S100A7 and invasive breast carcinoma: Importantly, in agreement with our in vitro cell line data (Figure 1B, C), analysis of TCGA invasive breast cancer patient data [24] showed that S100A7 overexpression in ER+ patients is more likely to correlate with miR-29b upregulation than ER− patients; and S100A7 overexpression in ER− patients is more likely to correlate with miR-29b downregulation than ER+ patients (Additional file 1: Figures S1, S2 and S3).